These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21464405)

  • 41. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.
    Müller MC; Cortes JE; Kim DW; Druker BJ; Erben P; Pasquini R; Branford S; Hughes TP; Radich JP; Ploughman L; Mukhopadhyay J; Hochhaus A
    Blood; 2009 Dec; 114(24):4944-53. PubMed ID: 19779040
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Systemic dasatinib fails to prevent development of central nervous system progression in a patient with BCR-ABL unmutated Philadelphia chromosome-positive leukemia.
    Frigeri F; Arcamone M; Luciano L; Di Francia R; Pane F; Pinto A
    Blood; 2009 May; 113(20):5028-9. PubMed ID: 19443672
    [No Abstract]   [Full Text] [Related]  

  • 43. The beauty and the beast: lymphoma-like morphology of myeloid blast phase in CML.
    Asemissen AM; Dierlamm J
    Blood; 2017 Sep; 130(10):1274. PubMed ID: 28882836
    [No Abstract]   [Full Text] [Related]  

  • 44. Hematology: dasatinib regimens for patients with chronic myeloid leukemia.
    Guilhot F; Roy L
    Nat Rev Clin Oncol; 2009 Dec; 6(12):680-2. PubMed ID: 19942922
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dasatinib for the treatment of chronic myeloid leukemia.
    Fullmer A; Kantarjian H; Cortes J; Jabbour E
    Expert Rev Hematol; 2011 Jun; 4(3):253-60. PubMed ID: 21668392
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Molecular targeting therapy for chronic myeloid leukemia].
    Kimura S
    Rinsho Ketsueki; 2007 Jan; 48(1):46-55. PubMed ID: 17313076
    [No Abstract]   [Full Text] [Related]  

  • 47. Second generation tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia. [An interview with Hagop Katarjian by H&O].
    Kantarjian H
    Clin Adv Hematol Oncol; 2008 Nov; 6(11):797-9. PubMed ID: 19194361
    [No Abstract]   [Full Text] [Related]  

  • 48. Dasatinib: a new step in molecular target therapy.
    Olivieri A; Manzione L
    Ann Oncol; 2007 Jun; 18 Suppl 6():vi42-6. PubMed ID: 17591830
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia.
    De Melo VA; Milojkovic D; Khorashad JS; Marin D; Goldman JM; Apperley JF; Reid AG
    Blood; 2007 Oct; 110(8):3086-7. PubMed ID: 17916757
    [No Abstract]   [Full Text] [Related]  

  • 50. Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V.
    Ustun C; Corless CL; Savage N; Fiskus W; Manaloor E; Heinrich MC; Lewis G; Ramalingam P; Kepten I; Jillella A; Bhalla K
    Leuk Res; 2009 May; 33(5):735-41. PubMed ID: 18986703
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pediatric chronic myeloid leukemia with myeloid blast crisis and complex karyotype at presentation.
    Sazawal S; Singh K; Chhikara S; Chaubey R; Mishra P; Seth T; Saxena R
    Indian J Cancer; 2020; 57(3):343-345. PubMed ID: 32769290
    [No Abstract]   [Full Text] [Related]  

  • 52. Extramedullary blastic crisis in abdominal lymph nodes in a patient with chronic myelogenous leukemia on imatinib.
    Shune L; Cayci Z; Rogosheske J; Brunstein C; Ustun C
    Leuk Res; 2012 Jun; 36(6):e131-2. PubMed ID: 22444689
    [No Abstract]   [Full Text] [Related]  

  • 53. [Ponatinib: new option for the treatment of resistant chronic myeloid leukemia].
    Camañas-Troyano C; Calderón-Acedos C; Moriel-Sánchez Mdel C; Segura-Bedmar M
    Farm Hosp; 2013; 37(5):428-9. PubMed ID: 24128110
    [No Abstract]   [Full Text] [Related]  

  • 54. Hematology: Nilotinib and dasatinib--new 'magic bullets' for CML?
    Breccia M
    Nat Rev Clin Oncol; 2010 Oct; 7(10):557-8. PubMed ID: 20877419
    [No Abstract]   [Full Text] [Related]  

  • 55. [Dasatinib monotherapy for intramedullary T-lymphocyte blast crisis in chronic myeloid leukemia: a case report].
    Zhang Y; Yang JB; Ma YM
    Zhonghua Xue Ye Xue Za Zhi; 2024 Jun; 45(6):608-609. PubMed ID: 39134498
    [No Abstract]   [Full Text] [Related]  

  • 56. Circumventing resistance to kinase-inhibitor therapy.
    Druker BJ
    N Engl J Med; 2006 Jun; 354(24):2594-6. PubMed ID: 16775240
    [No Abstract]   [Full Text] [Related]  

  • 57. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.
    Cortes J; Kim DW; Raffoux E; Martinelli G; Ritchie E; Roy L; Coutre S; Corm S; Hamerschlak N; Tang JL; Hochhaus A; Khoury HJ; Brümmendorf TH; Michallet M; Rege-Cambrin G; Gambacorti-Passerini C; Radich JP; Ernst T; Zhu C; Van Tornout JM; Talpaz M
    Leukemia; 2008 Dec; 22(12):2176-83. PubMed ID: 18754032
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.
    Kreutzman A; Juvonen V; Kairisto V; Ekblom M; Stenke L; Seggewiss R; Porkka K; Mustjoki S
    Blood; 2010 Aug; 116(5):772-82. PubMed ID: 20413659
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dasatinib is effective in imatinib-resistant CML.
    Cannell E
    Lancet Oncol; 2007 Apr; 8(4):286. PubMed ID: 17431950
    [No Abstract]   [Full Text] [Related]  

  • 60. Dasatinib-responsive chronic lymphocytic leukemia in a patient treated for coexisting chronic myeloid leukemia.
    Nagao T; Takahashi N; Kameoka Y; Noguchi S; Shinohara Y; Ohyagi H; Kume M; Sawada K
    Intern Med; 2013; 52(22):2567-71. PubMed ID: 24240798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.